AI assistant
Sending…
Aqua Bio Technology — Board/Management Information 2016
Jan 12, 2016
3535_iss_2016-01-12_03b20bf7-9b94-4ee1-b862-e9765c99fa62.pdf
Board/Management Information
Open in viewerOpens in your device viewer
AQUA BIO TECHNOLOGY ASA VALGKOMITEENS INNSTILLING TIL EKSTRAORDINÆR GENERALFORSAMLING 2. februar 2016 1. Valgkomiteens sammensetning og arbeid Valgkomiteen i Aqua Bio Technology ASA ("ABT") er nedfelt i selskapets vedtekter og velges av generalforsamlingen. Valgkomiteen i ABT har i dag følgende sammensetning: - Per Hagen - Roger Hofseth - Geir Christian Melen Valgkomiteen avgir innstilling til kandidater til selskapets styre og valgkomiteen og honorarer for medlemmer av disse. Valgkomiteen har hatt diskusjoner hvor styrets sammensetning har vært vurdert, herunder samtaler med styremedlemmer og administrerende direktør. Valgkomiteen har hatt kontakt med større aksjonærer og forankret sin innstilling. 2. Valgkomiteens innstilling til valg av ny styreleder Styret i selskapet består i dag av følgende personer: AQUA BIO TECHNOLOGY ASA NOMINATION COMMITTEE PROPOSAL FOR EXTRAORDINARY GENERAL MEETING 2 February 2016 1.Nomination committee's composition and proposal The nomination committee of Aqua Bio Technology AS ("ABT") is regulated by the company's articles of association and elected by the general meeting. Today, the nomination committee has the following members: - Per Hagen - Roger Hofseth - Geir Christian Melen The nomination committee proposes candidates for the board of directors of the company and their remuneration. The nomination committee has had discussions where the board's composition has been evaluated, including conversations with board members and the CEO. The nomination committee has had contact with large shareholders and has backing for its proposal from them. 2.Nomination committee's proposal for new election of new chairman The board of directors currently comprises the following members:
In case of discrepancy between the Norwegian language original text and the English language translation, the Norwegian text shall prevail
| - | - |
|---|---|
| John Afseth, styreleder | John Afseth, chaiman |
| - | - |
| Tone Bjørnov | Tone Bjørnov |
| - | - |
| Jan Pettersson | Jan Pettersson |
| - | - |
| Kristin Aase | Kristin Aase |
| Styrets leder John Afseth ønsker av private årsaker begrunnet i for stor arbeidsbelastning å fratre sitt styreverv i Selskapet. Valgkomiteen innstiller Edvard Cock som dets kandidat til ny styreleder. Edvard Cock er advokat og Partner i Advokatfirmaet CLP DA og arbeider til daglig med primært spørsmål relatert til kapitalmarkeder, fusjoner, bedriftsoppkjøp, salg, restrukturering og andre egenkapitaltransaksjoner. Cock har i tillegg til juridisk utdannelse, en toårig MBA fra Ross School of Business at the University of Michigan, med spesialisering innen finans, regnskap og private equity/venture capital. Cock har betydelig erfaring fra forhandlinger. (Se mer om Edvard her: http://www.clp.no/mobile#employee/edvard cock) De øvrige styremedlemmer fortsetter i sine respektive verv. |
The chairman, John Afseth, wishes to resign from this position for personal reasons due to too big a work load. The nomination committee proposes that Edvard Cock be elected as new chairman. Edvard Cock is an attorney-at-law and Partner with Advokatfirmaet CLP DA and works primarily with issues relating to capital markets, mergers, acquisitions, divestments, restructuring and other equity transactions. In addition to a legal degree, Cock has a two year MBA from Ross School of Business at the University of Michigan, with specializations within finance, accounting and private equity/venture capital. Cock has vast experience from negotiations. (Read more about Edvard here: http://www.clp.no/mobile#employee/edvard cock) The other board members will remain in their current positions. |
Oslo, 12. januar 2016 / 12 January 2015
Geir Christian Melen (sign.) Per Hagen (sign.) Roger Hofseh (sign.)
More from Aqua Bio Technology
Proxy Solicitation & Information Statement
2026
May 27
Proxy Solicitation & Information Statement
2026
May 27
Proxy Solicitation & Information Statement
2026
May 27
Report Publication Announcement
2026
May 27
Report Publication Announcement
2026
Apr 27
Share Issue/Capital Change
2026
Apr 21
Report Publication Announcement
2026
Apr 21
Report Publication Announcement
2026
Apr 21
Capital/Financing Update
2026
Apr 10
Capital/Financing Update
2026
Apr 10